Amgen Prepares Eylea Biosimilar Launch Amid Ongoing Legal Battles with Regeneron

Amgen secured a significant court victory when a trio of U.S. Circuit Judges denied Regeneron's attempt to block the launch of Amgen's Eylea biosimilar, Pavblu[1]. This decision lifted the injunction that had been in place and allowed Amgen to proceed with the launch, albeit "at risk" due to ongoing patent infringement claims by Regeneron[2]. The court win follows Amgen's recent FDA approval for its biosimilar, paving the way for its entry into a market where Regeneron's Eylea is a major revenue driver[1]. Despite the favorable ruling, the legal battle is set to continue, with expedited proceedings scheduled[2].